OncoBeta® GmbH located in Garching near Munich is a manufacturer and service provider of innovative medical solutions specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotopes.

We are very proud to be a pioneer and innovator in the epidermal radioisotope sector, presently offering a therapeutic application for physicians to treat non-melanoma skin cancer. Our current flag ship solution is the Rhenium-SCT® (Skin Cancer Therapy) a novel treatment option for basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs) based on the local irradiation of tumors with the beta-emitter Rhenium-188.
Rhenium-188 is an optimal isotope for the treatment of superficial lesions such as non-melanoma skin cancers due to its practical penetration of 2-3mm in human tissue. 

Since the radioactive Rhenium does not come in direct contact with the patient, the Rhenium-SCT® is seen as a patient-personalised brachytherapy with minimal radiation exposition and adverse effects. 

The Rhenium-SCT is a CE certified method arising from over 10 years of experience and clinical studies (>700 patients, >1900 lesions). It provides non-melanoma skin cancer patients with a single-session, painless, highly-effective non- surgical treatment with excellent aesthetic results and complete remissions in up to 98,5% of all cases. 

We are also currently evaluating further exciting applications and treatment possibilities with rhenium-188.

Health Care

Medical Devices

Nuclear

Therapeutics

OncoBeta - epidermal radioisotope therapy

OncoBeta - epidermal radioisotope therapy's headquarters in Garching, Germany

Nicholas H. Vetter

Lachlan Hicks

Birgit Schönlein

Shannon Brown III

Martin Reuter

Dr Sam Vohra

Cody Allison

Description

People (5)

Nicholas H. Vetter

Dimitri Münch

Martin Reuter

Juho Nikula

Shannon Brown III

Jobs